Ionis delays prion disease readout; Arvinas’ Parkinson’s biomarker datanews2026-03-18T14:17:05+00:00March 18th, 2026|Endpoints News|
Pfizer’s next-gen breast cancer data; Bristol Myers’ PRMT5 candidatenews2026-03-17T14:24:48+00:00March 17th, 2026|Endpoints News|
CytomX reports ADC data in late-line colorectal cancer; FDA OKs Cosentyx label expansionnews2026-03-16T13:38:35+00:00March 16th, 2026|Endpoints News|
Y-mAbs terminates radiopharma trial; GSK gets expanded use for Arexvynews2026-03-13T13:48:06+00:00March 13th, 2026|Endpoints News|
UCB says Bimzelx tops Skyrizi in trial; Xenon, Dianthus set share salesnews2026-03-11T14:52:55+00:00March 11th, 2026|Endpoints News|
Ascletis touts GLP-1 quarterly dosing data; Mineralys apnea Phase 2 missesnews2026-03-10T15:02:46+00:00March 10th, 2026|Endpoints News|
AbbVie, Gubra post obesity data; Regeneron obesity drug succeeds in Chinanews2026-03-09T15:17:36+00:00March 9th, 2026|Endpoints News|
Solid Biosciences gets $240M for pipeline; Roche expounds on lupus datanews2026-03-06T15:35:55+00:00March 6th, 2026|Endpoints News|
Bayer continues trimming workforce; AnaptysBio’s spinoff is namednews2026-03-04T15:56:40+00:00March 4th, 2026|Endpoints News|
Prolium’s $50M Series A raise; COUR Pharma touts liver drug follow-upnews2026-03-03T15:32:03+00:00March 3rd, 2026|Endpoints News|
